Our mission is to establish new equilibriums – both in patients’ immune responses and in the field of immunotherapy.
As a clinical-stage company focused on specialized cell immunotherapy, we intend to develop and commercialize an allogeneic drug pipeline for rebalancing all manner of immune hyper-responses.
Our pioneering Allocetra™ cell-based therapy breaks with old paradigms, offering to effectively treat numerous acute conditions through a radically different clinical approach. By using the body’s native mechanisms to restore – rather than suppress – immune balance, we aim to reshape the way immune, autoimmune, and inflammatory conditions are both thought of and treated.
Advanced clinical-stage pipeline
with promising Phase II results
Short regulatory approval pathway
FDA & EU orphan designations; Specialized Life-Threatening Regulation in Europe potentially enables post-Phase II marketing approval
BMT, Sepsis, Solid tumors
Take a look at our company overview
inspired by great science and a sense of mission
Our management, clinical advisors, personnel, and affiliates have extensive knowledge in the treatment of immune and inflammatory disorders, and expertise in the research and development of therapies based on apoptotic cell clearance.
Shmuel Hess, Ph.D.
Chief Executive Officer
Prof. Dror Mevorach, M.D.
Chief Scientific & Medical Officer
Head of Clinical Operations
Head Of CMC
Abraham Havron, Ph.D.
Bernhard Kirschbaum, Ph.D.
Hyun Gyu Lee, Ph.D., M.D.
Gili Hart, Ph.D.
Dr. Paul J. Martin, MD
Fred Hutchinson Cancer Research Center, University of Washington
Dr. Mohamad Mohty, MD, PHD
Saint-Antoine Hospital, Paris
Dr. James Ferrara, MD
The Icahn School of Medicine at Mount Sinai
Dr. Mitchell Levy, MD, MCCM
The Warren Alpert Medical School of Brown University
Dr. Clifford Deutschman, MD
The Feinstein Institute for Medical Research